The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD

Bone Marrow Transplantation

Volumn 51, Issue 2, 2016, Pages 273-276

  Nadeau, M ^a   Perreault, S ^a   Seropian, S ^a   Foss, F ^a   Isufi, I ^a   Cooper, D L ^a  

^a YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; INFLIXIMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM SURVIVAL; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; ACUTE DISEASE; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84956914547     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.247     Document Type: Article

References (21)

1. Antin JH. Steroid-refractory acute graft-versus-host disease: is there an effective therapy? Biol Blood Marrow Transplant 2014; 20: 146-148
2. Jamani K, Russell JA, Daly A, Stewart D, Savoie L, Duggan P et al. Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant 2013; 48: 1359-1361
3. Martin PJ, Inamoto Y, Flowers ME, Carpenter PA. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 2012; 18: 982-988
4. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101
5. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777-786
6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
7. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-843
8. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902
9. Deeg HJ. How I treat refractory acute GVHD. Blood 2007; 109: 4119-4126
10. Copelan E, Casper JT, Carter SL, van Burik JAH, Hurd D, Mendizabal AM et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007; 13: 1469-1476
11. Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versushost disease after allogeneic stem cell transplantation. Ann Hematol 2014; 93: 855-861
12. Gassas A, Sung L, Dupuis A, Schechter T, Egeler M, Ali M. Acute gut GVHD in children: does skin involvement matter? Bone Marrow Transplant 2013; 48: 1129-1132
13. Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014; 124: 363-373
14. Rager A, Frey N, Goldstein SC, Reshef R, Hexner EO, Loren A et al. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroidrefractory acute GVHD. Bone Marrow Transplant 2011; 46: 430-435
15. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511-517
16. Bolanos-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014; 124: 3221-3227
17. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104: 1559-1564
18. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789
19. Funke VA, Medeiros CR, Setubal DC, Ruiz J, Bitencourt MA, Bonfim CM et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006; 37: 961-965
20. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graftversus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899-903
21. Wang JZ, Liu KY, Xu LP, Liu DH, Han W, Chen H et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc 2011; 43: 1928-1933